Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Umecrine Mood Announces Completion of Patient Recruitment

Published: Friday, December 20, 2013
Last Updated: Friday, December 20, 2013
Bookmark and Share
Patient recruitment in the phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms.

Umecrine Mood AB has announced that patient recruitment for the ongoing phase I/II study with UC1010 for the treatment of severe premenstrual symptoms (PMDD) has been completed. Umecrine Mood is part of the Karolinska Development portfolio.

“About half of the patients planned for the study have completed the treatment. The remaining participants are currently in treatment or will be treated during the coming months, as soon as diagnosis has been completed. The aim is to present the first results during Q2 2014. We would like to take the opportunity to thank all of you that have showed an interest in participating in the study”, says Karin Ekberg, CEO of Umecrine Mood.

Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms are so severe that the women are considered to be suffering from PMDD. This implies that the symptoms significantly affect the women’s daily life and relationships to other people.

The basis for the symptoms relates to an altered sensitivity to a breakdown product of a sex hormone that affects the brain's emotional center.

Umecrine Mood is the first company to successfully develop compounds that are proven to reduce the activity of the breakdown product in healthy individuals, and now the selected candidate drug UC1010 is tested in patients for the first time.

"The current treatments of PMDD consist primarily of antidepressant drugs, which are not specifically developed for PMDD. These drugs are not always effective and often cause side effects. There is no doubt that these women are in need of an effective and targeted treatment”, says Karin Ekberg.

The multi-center study is double-blind and placebo controlled and will include about 120 individuals. Coordinating Investigator is Professor Marie Bixo, Institute of Clinical Research and Education, Södersjukhuset, Karolinska Institutet.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Positive Results from an Exploratory Phase I/II Study with UC1010 in PMDD
Results show a significant improvement of symptoms in patients treated with UC1010.
Tuesday, September 23, 2014
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos